A major project to redesign the UK’s pharma supply chain has moved into the next phase following £11.2 million ($17.7 million) of government funding,
The REMEDIES project was launched in 2014 and headed by GlaxoSmithKline (LSE: GSK) with research led by the University of Cambridge’s Institute for Manufacturing. It is due to be completed in March 2018 and has several technology-based projects underpinned by two platform projects: clinical trials supply chains led by GSK and commercial supply chains led by the Institute for Manufacturing. The announcement of the new government funding, and a further £11 million from industry means that expenditures can now be approved and the project will move into the technology application phase.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze